{"id":"W3084155739","doi":"10.1038/s41416-020-01041-x","title":"Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"National Cancer Institute; Takeda Oncology; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Tolerability; Endometrial cancer; Medicine; Pharmacodynamics; Renal cell carcinoma; Pharmacokinetics; Rash; Internal medicine; Bladder cancer; Urology; Dosing; Cancer; Carcinoma; Oncology; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001461571,0.001310154,0.001609618,0.0003991115,0.0004032849,0.0005479625,0.0007279429,0.0007329573,0.002544465],"category_scores_gemma":[0.0005444717,0.0005044689,0.00087735,0.0003428854,0.0006328437,0.0005508368,0.0003442273,0.002752024,0.0005735201],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007641911,"about_ca_system_score_gemma":0.001617799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007658986,"about_ca_topic_score_gemma":0.00229741,"domain_scores_codex":[0.999637,0.0001420739,0.00001893446,0.00006846614,0.00005407458,0.00007939206],"domain_scores_gemma":[0.9994012,0.00008201131,0.000119804,0.00005420141,0.00004897983,0.0002937302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3307804,0.1679266,0.01327964,0.001575049,0.001238134,0.0009952805,0.0007573591,0.007220729,0.3054521,0.0003781893,0.007788469,0.1626081],"study_design_scores_gemma":[0.2622933,0.6899213,0.01772217,0.00004363329,0.0004117475,0.0009076621,0.00006555014,0.002225018,0.02284686,0.0001762769,0.003348034,0.00003847761],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964213,0.0008870678,0.0003556522,0.0001719689,0.00003259361,0.001116351,0.0003386892,0.00005791192,0.0006185038],"genre_scores_gemma":[0.9914937,0.0009879479,0.002035669,0.0004384832,0.00007407129,0.00170596,0.001816396,0.00003102036,0.001416717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002544465,"threshold_uncertainty_score":0.00851208,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02676153683504138,"score_gpt":0.3543512937309712,"score_spread":0.3275897568959298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}